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ABSTRACT: RABORAL V-RGHa is a recombi-
nant vaccine used in oral rabies vaccination
(ORV) programs for wildlife in the United
States. Vaccination rates for raccoons are
substantially lower than vaccination rates for
gray foxes and coyotes. Research suggests that
the low viscosity of the oral vaccine may
preclude animals from receiving an effective
dose when biting into the vaccine bait delivery
system. We evaluated the possibility of using
two benign compounds, chitosan and N,N,N-
trimethylated chitosan (TMC), to increase the
viscosity of the vaccine and potentially act as
adjuvants to improve the immune response in
raccoons (Procyon lotor). Forty mildly sedated
raccoons were orally vaccinated via needleless
syringe with either RABORAL V-RG (n512),
chitosan+RABORAL V-RG (n512), TMC+
RABORAL V-RG (n512), or no vaccine
(n54), on day 0 and again on day 90. We
collected sera every 2–4 wk for 4 mo and
evaluated rabies virus-neutralizing antibodies
(rVNA). Raccoons were considered responders
if rVNA titers were $0.1 IU/mL. Eleven of 12
raccoons vaccinated with TMC+RABORAL
V-RG responded after one dose of vaccine, as
did eight of 12 vaccinated with RABORAL V-
RG, and three of 12 vaccinated with chitosan+
RABORAL V-RG. Our results suggest that the
inclusion of an adjuvant, such as TMC, could
increase vaccine efficacy to aid in controlling
rabies virus spread in wildlife reservoirs.
Key words: Adjuvant, chitosan, oral vacci-
nation, rabies, raccoon, vaccine.
In North America, rabies is maintained
by wildlife reservoirs. To reduce the
prevalence of rabies in wild carnivores,
RABORAL V-RGH (Merial Ltd., Athens,
Georgia, USA) oral rabies vaccines (ORV)
are distributed in the United States east of
the Appalachian Mountains, as well as
portions of Ohio, Arizona, New Mexico,
and Texas. Vaccination rates in Texas have
been sufficiently high to control rabies in
gray fox (Urocyon cinereoargenteus) and
coyotes (Canis latrans; Fearneyhough
et al., 1998; Sidwa et al., 2005). Eisinger
and Thulke (2008) suggest that a vaccina-
tion rate of 60% is sufficient to break the
pathogen transmission cycle; however, the
ORV program in the United States suc-
cessfully vaccinates only about 30% of
raccoons (Procyon lotor) (Slate et al.,
2009).
The RABORAL V-RG vaccine is deliv-
ered as a liquid contained within a plastic
sachet coated with fish meal or a sachet
surrounded within a fish-meal polymer.
Under optimal conditions, when the
sachet is pierced by an animal, the vaccine
is released into the mouth, coating the
mucosae. The recombinant vaccine atta-
ches and enters host cells and expresses
the rabies virus glycoprotein, triggering an
immune response. It is unknown why
vaccination rates in raccoons are lower
than gray foxes and coyotes. One reason
could be that the vaccine is not as
immunogenic in raccoons, suggesting the
need for an adjuvant. Another reason
could be vaccine spillage, suggesting the
need for a more viscous vaccine mixture.
While foxes and coyotes tend to pick up
the entire bait with their mouth, releasing
a full dose of vaccine into the buccal cavity
as they chew, raccoons hold the vaccine
sachet on the ground and bite only small
portions at a time, allowing the open
sachet to leak. Pen trials have repeatedly
shown raccoons spilling much of the liquid
contents of the sachet (Brown et al., 2011).
We investigated two compounds with
adjuvant properties that also increase
vaccine viscosity: chitosan and N,N,N-
trimethylated chitosan (TMC). Chitin is a
nontoxic polymer that naturally occurs in
crustaceans, insects, and mushrooms.
a RABORAL V-RGH is a registered trademark of Merial
Ltd. (Athens, Georgia, USA). All other marks are the
property of their respective owners.
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When chitin is deacetylated, it becomes
chitosan, a safe, natural cationic polysac-
charide that is highly biodegradable, has a
relatively neutral pH when combined
with a phosphate buffer solution, and has
low toxicity (Dodane et al., 1999). When
neutralized, chitosan forms a gelatinous
precipitate, which increases the bioavail-
ability of vaccines or drugs (Baudner et al.,
2004) and enhances transport and absorp-
tion across the epithelial barrier by
disrupting tight junctions in the mucosa
and activating macrophages and cytotoxic
T-lymphocytes (van der Lubben et al.,
2001). The compound TMC is a chitosan
derivative that exhibits similar utility as a
thickener and adjuvant (LueBen et al.,
1996). TMC is more soluble at neutral pH
than chitosan, but it maintains the immu-
nogenic and adhesive properties of chit-
osan (Kotze et al., 1997).
TMC was produced from commercially
available chitosan (Sigma-Aldrich, St.
Louis, Missouri, USA). Multiple additions
of methyl iodine were made into a suspen-
sion of finely ground chitosan in N-
methylpyrrolidone, and sodium hydroxide
(NaOH) was added to neutralize the
hydroiodic acid by-product. When the
reaction was completed, the mixture was
dialyzed against multiple changes of sodi-
um chloride (NaCl) solutions. The result-
ing dialysis product was freeze-dried to
yield TMC powder. TMC was made into a
stock solution concentration of 5% in
Roswell Park Memorial Institute media
(RPMI; Sigma-Aldrich), while the limited
solubility of chitosan dictated a 1% chitosan
stock solution. Both solutions were steril-
ized by autoclaving prior to mixing with
RABORAL V-RG. Our objective was to
determine if the addition of either chitosan
or TMC affected the humoral immune
response of raccoons to RABORAL V-RG.
Forty raccoons were trapped using
appropriate-sized TOMAHAWK Live
TrapsH (Hazelhurst, Wisconsin, USA) in
Larimer County, Colorado (40u35.4039 N,
105u9.1469 W). Raccoons were housed
individually in 33332.5-m pens that
included den boxes and enrichment struc-
tures at the US Department of Agriculture
National Wildlife Research Center’s Out-
door Animal Research Facility (Fort
Collins, Colorado, USA) for the duration
of the study. Prior to the experiment,
raccoons were evaluated for health after
intramuscular administration with 10 mg/
kg ketamine HCl and 2 mg/kg xylazine
(Deresienski and Rupprecht, 1989). Ivo-
mecH (0.1 mL/5kg, per os, Merial) was
also administered to raccoons to control
internal parasites, and raccoons were
vaccinated for distemper with the GAL-
AXY DH vaccine (Schering-Plough Animal
Health Corporation, Boxmeer, The Neth-
erlands) and microchipped (Avid Identifi-
cation Systems, Inc., Norco, California,
USA). Blood was collected via venipunc-
ture of the jugular vein to measure
baseline rabies virus-neutralizing antibody
(rVNA) titers. Raccoons were quarantined
for a minimum of 14 days. The Institu-
tional Animal Care and Use Committee at
the National Wildlife Research Center
approved all experimental procedures
and animal holding conditions.
Prior to the experiment, the RABORAL
V-RG vaccine titer was determined to be
107.4 50% Tissue culture infectious dose
(TCID50)/mL. Three vaccine formulations
were prepared in 2-mL dosages: 2 mL of
RABORAL V-RG alone (107.7 TCID50),
1 mL of RABORAL V-RG+1 mL of 1%
chitosan (107.4 TCID50), and 1 mL of
RABORAL V-RG+1 mL of 5% TMC
(107.4 TCID50). Antibody-negative rac-
coons were randomly placed into one of
four groups: chitosan+RABORAL V-RG
(n512), TMC+RABORAL V-RG (n512),
RABORAL V-RG only (n512), or no
vaccine (n5 4). After sedation with 10
mg/kg ketamine HCl and 2 mg/kg xylazine,
blood was collected from each raccoon, and
2-mL aliquots of the vaccine mixture were
delivered via needleless syringe into the
mouth. Raccoons swallowed the mixture,
and the volume of the vaccine consumed
was confirmed. The day of vaccination was
considered 0 days postinoculation (dpi).
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On 90 dpi, all raccoons received a 2-mL
booster dose of the vaccine formulation or
placebo vaccine (two raccoons were eutha-
nized for health reasons unrelated to the
study before 90 dpi). To follow rVNA
development, animals were anesthetized
and blood was collected at 4, 14, 21, 28, 60,
90, 104, and 126 dpi. Rabies VNA titers
were measured at the Centers for Disease
Control and Prevention, Atlanta, Georgia,
USA, using the rapid fluorescent focus
inhibition test (RFFIT), as described by
Smith et al. (1996).
We considered raccoons with rVNA
titers $0.1 IU/mL to be responders.
Table 1 summarizes the mean and range
of rVNA titers over the course of the study.
The chitosan+RABORAL V-RG vaccine
was consistently less effective at eliciting
a humoral immune response than either
the RABORAL V-RG vaccine or the
TMC+RABORAL V-RG vaccine (Table 2).
Before the 90 dpi booster, 11 of 12 raccoons
vaccinated with TMC+RABORAL V-RG
responded with rVNA $ 0.1 IU/mL, as
compared with eight of 12 raccoons
vaccinated with RABOARL V-RG alone.
Logistic regression suggested that vacci-
nation with TMC+RABORAL V-RG
(P,0.01) and RABOARL V-RG (P,0.05)
resulted in a greater number of respond-
ers than the chitosan+RABORAL V-RG
treatment group prior to the boost vacci-
nation at day 90. Using the Wald test to
compare factors within the logistic regres-
sions, there was not a significant difference
between TMC+RABORAL V-RG and RA-
BOARL V-RG (P50.16). After the vaccine
booster, logistic regression demonstrated
there was no difference between vaccine
formulations (P50.997). However, rabies
VNA titers among the three vaccine
combinations were significantly different
(F3,3259.07, P,0.001), with raccoons re-
ceiving TMC+RABORAL V-RG producing
higher rVNA titers.
Exploration into mucosal adjuvants pro-
vides at least two potential avenues to
TABLE 1. Summary of rabies virus-neutralizing antibodies (IU/mL) in raccoons (Procyon lotor) vaccinated
with RABORAL V-RG, trimethylated chitosan combined with RABORAL V-RG (TMC+RABORAL V-RG),
chitosan combined with RABORAL V-RG (chitosan+RABORAL V-RG), or nonvaccinated control raccoons
from day 0 to day 126 postvaccination.
Days postvaccination RABORAL V-RG TMC+RABORAL V-RG Chitosan+RABORAL V-RG No vaccine
0 0.04a (12)b 0.04 (12) 0.04 (12) 0.04 (4)
0.04–0.04c 0.04–0.04 0.04–0.04 0.04–0.04
7 0.056 (12) 0.04 (12) 0.04 (12) 0.04 (4)
0.04–0.104 0.04–0.04 0.04–0.04 0.04–0.04
14 0.202 (12) 0.192 (12) 0.069 (12) 0.04 (4)
0.04–0.448 0.04–0.448 0.04–0.336 0.04–0.040
21 0.188 (12) 0.334 (12) 0.093 (12) 0.04 (4)
0.04–0.4 0.04–0.488 0.04–0.40 0.04–0.04
28 0.232 (12) 0.307 (12) 0.126 (12) 0.073 (4)
0.04–0.488 0.04–0.448 0.04–0.48 0.05–0.08
60 0.456 (12) 0.582 (12) 0.155 (12) 0.05 (4)
0.05–0.62 0.05–0.89 0.05–0.620 0.05–0.05
90 0.32 (11) 0.484 (12) 0.168 (11) 0.08 (4)
0.05–0.62 0.05–0.62 0.05–0.62 0.08–0.08
104 0.792 (11) 0.838 (12) 0.391 (11) 0.08 (4)
0.16–0.89 0.60–0.89 0.08–0.89 0.08–0.08
126 0.758 (11) 0.811 (12) 0.457 (11) 0.08 (4)
0.18–0.89 0.180–0.890 0.08–0.89 0.08–0.08
a Mean (IU/mL).
b Sample size (n).
c rVNA range (IU/mL).
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increase effectiveness of this vaccine in
raccoons: 1) increasing the host’s immu-
nologic response to the vaccination and 2)
increasing vaccine viscosity. Chitosan and
its derivatives have been used as adjuvants
in drug-delivery systems; however, we are
the first to test these mucosal adjuvants
with the RABORAL V-RG rabies vaccine.
After a dose of chitosan+RABORAL V-
RG, only three of 12 individuals produced
rVNA, and after a booster vaccination with
the same mixture, only seven of 11
raccoons had detectable rVNA. One pos-
sible explanation for the lack of responders
in the chitosan+RABORAL V-RG treat-
ment group may be related to the physical
and chemical properties of chitosan upon
vaccine administration. First, unlike TMC,
chitosan is not water soluble, which may
decrease its utility in the oral cavity
particularly when the vaccine is adminis-
tered by direct instillation, as we did in
this study. Consequently, the chitosan–
vaccine mixture may not be sustained in
the oral cavity long enough to allow
adequate vaccine uptake. Secondly, vac-
cine uptake could also have been compro-
mised if chitosan encapsulated the vac-
cine, thus limiting the availability of
RABORAL V-RG.
While one dose of the current RA-
BORAL V-RG formulation was enough to
produce rVNA in eight of 12 individuals,
only after a booster vaccination did 100%
of raccoons exhibit rVNA titers high
enough to be considered responders. We
found the TMC+RABORAL V-RG results
more promising; after one vaccination
with a TMC+RABORAL V-RG mixture,
11 of 12 raccoons had detectable rVNA.
Although not significantly higher than the
number of raccoons vaccinated with RA-
BORAL V-RG alone, animals receiving
the TMC+RABORAL V-RG vaccine re-
ceived only half the vaccine dose (107.4
TCID50) recommended by the manufac-
turer. Similar to RABORAL V-RG alone,
a booster vaccination with the TMC+
RABORAL V-RG mixture led to a 100%
success rate.
While these results should be interpret-
ed cautiously due to our small sample size,
our findings offer improvements to the
limitations of RABORAL V-RG, especially
in relation to species that are currently
difficult to vaccinate with the current
vaccine formulation, and may offer bene-
fits for enhancing the immunogenicity
through the adjustment of physical prop-
erties of the vaccine. Improvements in the
efficiency of vaccine delivery and immu-
nogenicity of RABORAL V-RG is crucial
because obtaining a threshold effect for
herd immunity is necessary to curtail the
spread of rabies in wildlife reservoirs. The
addition of TMC to RABORAL V-RG did
not decrease the immunogenicity of the
vaccine; however, we did not investigate
how the new formulation affected vaccine
delivery, including uptake by raccoons
handling the vaccine sachet. Our conclu-
sions show potential for the next level of
investigation to evaluate how raccoons
handle the more viscous vaccine and if
those changes affect the number of
raccoons successfully vaccinated by new
formulations of RABORAL V-RG. Future
research will involve allowing raccoons to
consume the vaccine, increasing the sam-
ple size, and decreasing the titer of
TABLE 2. Summary of the number of individual raccoons (Procyon lotor) responding to RABORAL V-RGH
vaccine formulations.
Treatment
No. raccoons with rabies VNA $0.1 IU/mL
prior to boost at 90 days (n)
No. raccoons with rabies VNA
$0.1 IU/mL after boost at 90 days (n)
RABORAL V-RG 8 (12) 11 (11)
Chitosan+RABORAL V-RG 3 (12) 7 (11)
TMC+RABORAL V-RG 11 (12) 12 (12)
No vaccine 0 (4) 0 (4)
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RABORAL V-RG to determine if TMC is
acting as an adjuvant.
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